Literature DB >> 29030692

Changes in aqueous concentrations of various cytokines after intravitreal bevacizumab and subtenon triamcinolone injection for diabetic macular edema.

Seung-Young Yu1, Dong Heun Nam2, Dae Yeong Lee3.   

Abstract

PURPOSE: The purpose of this study was to compare the changes in the aqueous cytokine levels after intravitreal bevacizumab with those after combined intravitreal bevacizumab and subtenon triamcinolone injection in diabetic macular edema (DME).
METHODS: This study examined 24 eyes of 23 patients with DME. Each patient with DME received randomly either an intravitreal injection of bevacizumab (IVBe) or IVBe with a subtenon triamcinolone injection (IVBe + STTA). Best corrected visual acuity and foveal thickness were evaluated and aqueous samples were obtained before and 4 weeks after the injection. The aqueous concentrations of interleukin (IL)-6, IL-8, interferon-induced protein (IP)-10, monocyte chemotactic protein (MCP)-1, platelet-derived growth factor (PDGF)-AA, and vascular endothelial growth factor (VEGF) were measured using a multiplex bead assay.
RESULTS: After the injection, the foveal thickness decreased more in the IVBe + STTA group than in the IVBe group (P = 0.042). The MCP-1, PDGF-AA, and VEGF levels decreased significantly in the IVBe + STTA group (p = 0.013, p = 0.004 and p = 0.018 respectively), but only the VEGF level decreased in the IVBe group (p = 0.001). IL-8 was significantly increased in the IVBe + STTA group (p = 0.003) but the changes in the VEGF levels were smaller than in the IVBe group (p = 0.025).
CONCLUSION: Intravitreal bevacizumab and subtenon triamcinolone injection reduces the VEGF, MCP-1 and PDGF-AA levels and increases the IL-8 level in the plural cytokine profiles of patients with DME, which might explain the limited therapeutic effect of combination therapy.

Entities:  

Keywords:  Aqueous cytokines; Bevacizumab; Combination therapy; Diabetic macular edema; Interleukin(IL)-8; Subtenon triamcinolone injection

Mesh:

Substances:

Year:  2017        PMID: 29030692     DOI: 10.1007/s00417-017-3819-2

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  33 in total

1.  Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion.

Authors:  H Noma; H Funatsu; M Yamasaki; H Tsukamoto; T Mimura; T Sone; T Hirayama; H Tamura; H Yamashita; A Minamoto; H K Mishima
Journal:  Eye (Lond)       Date:  2006-07-07       Impact factor: 3.775

2.  Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema.

Authors:  Sophie J Bakri; Peter K Kaiser
Journal:  Am J Ophthalmol       Date:  2005-02       Impact factor: 5.258

3.  Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion.

Authors:  Yukihiko Suzuki; Mitsuru Nakazawa; Kaori Suzuki; Hitoshi Yamazaki; Yasuhiro Miyagawa
Journal:  Jpn J Ophthalmol       Date:  2011-05-03       Impact factor: 2.447

4.  Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial.

Authors:  Florian K P Sutter; Judy M Simpson; Mark C Gillies
Journal:  Ophthalmology       Date:  2004-11       Impact factor: 12.079

5.  Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema.

Authors:  Hee Jin Sohn; Dae Heon Han; Im Tae Kim; In Kyung Oh; Kyun Hyung Kim; Dae Yeong Lee; Dong Heun Nam
Journal:  Am J Ophthalmol       Date:  2011-07-22       Impact factor: 5.258

6.  Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema.

Authors:  Hideharu Funatsu; Hidetoshi Yamashita; Tomohiro Ikeda; Tatsuya Mimura; Shuichiro Eguchi; Sadao Hori
Journal:  Ophthalmology       Date:  2003-09       Impact factor: 12.079

7.  Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy.

Authors:  Anna Praidou; Ioannis Klangas; Eleni Papakonstantinou; Sofia Androudi; Nikolaos Georgiadis; George Karakiulakis; Stavros Dimitrakos
Journal:  Curr Eye Res       Date:  2009-02       Impact factor: 2.424

8.  Angiotensin II increases expression of IP-10 and the renin-angiotensin system in endothelial cells.

Authors:  Noriko Ide; Tetsuaki Hirase; Ai Nishimoto-Hazuku; Yuji Ikeda; Koichi Node
Journal:  Hypertens Res       Date:  2008-06       Impact factor: 3.872

9.  Intravitreal injection of triamcinolone for diffuse diabetic macular edema.

Authors:  Jost B Jonas; Ingrid Kreissig; Antje Söfker; Robert F Degenring
Journal:  Arch Ophthalmol       Date:  2003-01

10.  Effect of Posterior Subtenon Triamcinolone Acetonide Injection on Diabetic Macular Edema Refractory to Intravitreal Bevacizumab Injection.

Authors:  Min Woo Kim; Haein Moon; Sung Jae Yang; Soo Geun Joe
Journal:  Korean J Ophthalmol       Date:  2016-01-21
View more
  10 in total

1.  Early and Late Switch from Ranibizumab to an Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema in the Event of a Poor Anatomical Response.

Authors:  Gokhan Demir; Abdullah Ozkaya; Elmas Yuksel; Gurkan Erdogan; Ugur Tunc; Mevlut Celal Ocal; Yasin Sakır Goker
Journal:  Clin Drug Investig       Date:  2020-02       Impact factor: 2.859

2.  Protein Microarrays for Ocular Diseases.

Authors:  Guillermo Solís-Fernández; Ana Montero-Calle; Miren Alonso-Navarro; Miguel Ángel Fernandez-Torres; Victoria Eugenia Lledó; María Garranzo-Asensio; Rodrigo Barderas; Ana Guzman-Aranguez
Journal:  Methods Mol Biol       Date:  2021

Review 3.  Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.

Authors:  Hemal Mehta; Charles Hennings; Mark C Gillies; Vuong Nguyen; Anna Campain; Samantha Fraser-Bell
Journal:  Cochrane Database Syst Rev       Date:  2018-04-18

4.  Aqueous humour cytokine changes during a loading phase of intravitreal ranibizumab or dexamethasone implant in diabetic macular oedema.

Authors:  Dominika Podkowinski; Eva Orlowski-Wimmer; Gerhard Zlabinger; Andreas Pollreisz; Anna-Sophie Mursch-Edlmayr; Siegfried Mariacher; Michael Ring; Matthias Bolz
Journal:  Acta Ophthalmol       Date:  2019-11-17       Impact factor: 3.761

5.  Relationship between aqueous humor cytokine level changes and retinal vascular changes after intravitreal aflibercept for diabetic macular edema.

Authors:  Rodolfo Mastropasqua; Rossella D'Aloisio; Marta Di Nicola; Giuseppe Di Martino; Alessia Lamolinara; Luca Di Antonio; Daniele Tognetto; Lisa Toto
Journal:  Sci Rep       Date:  2018-11-08       Impact factor: 4.379

Review 6.  A Systematic Review and Meta-Analysis of Clinical Outcomes of Intravitreal Anti-VEGF Agent Treatment Immediately after Cataract Surgery for Patients with Diabetic Retinopathy.

Authors:  Li-Quan Zhao; Jin-Wei Cheng
Journal:  J Ophthalmol       Date:  2019-04-16       Impact factor: 1.909

7.  The role of IL-6-174 G/C polymorphism and intraocular IL-6 levels in the pathogenesis of ocular diseases: a systematic review and meta-analysis.

Authors:  Zulvikar Syambani Ulhaq; Gita Vita Soraya; Lely Retno Wulandari
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

8.  Aqueous Level of ANGPTL4 Correlates with the OCTA Metrics of Diabetic Macular Edema in NPDR.

Authors:  Qing Xu; Chaoju Gong; Lei Qiao; Ruifang Feng; Haiyang Liu; Yalu Liu; Sujuan Ji; Yipeng Zhang; Shuang Wu; Suyan Li
Journal:  J Diabetes Res       Date:  2022-01-19       Impact factor: 4.011

9.  Intravitreal Ranibizumab Versus Intravitreal Ranibizumab Combined with Posterior Subtenon Triamcinolone Acetonide in Diabetic Macular Edema.

Authors:  Gamze Karatas; Burak Erden; Akin Cakir; Selim Bolukbasi; Serkan Erdenoz; Bora Deniz Argon; Mustafa Nuri Elcioglu
Journal:  Beyoglu Eye J       Date:  2021-09-27

10.  Vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema (DME)-results from the ILUVIT study.

Authors:  Svenja K Deuchler; Ralf Schubert; Pankaj Singh; Adonis Chedid; Ninel Kenikstul; Julia Scott; Thomas Kohnen; Hanns Ackermann; Frank Koch
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-03       Impact factor: 3.535

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.